Market PotentialZUNVEYL is expected to generate significant annual sales based on the long-term care market segment alone, with potential to reach $540M in peak annual sales in the U.S.
Product LaunchThe launch metrics for ZUNVEYL are promising, with positive feedback from prescribers and no reported adverse events.
Sales ForecastAlpha Cognition's sales exceeded expectations, leading to an increase in sales forecasts for the upcoming years.